Yüklüyor......
An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce major cardiovascular (CV) events in patients with type 2 diabetes mellitus. In this review, we assessed the CV outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors in terms of...
Kaydedildi:
| Yayımlandı: | Anatol J Cardiol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Turkish Society of Cardiology
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8114646/ https://ncbi.nlm.nih.gov/pubmed/33583813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14744/AnatolJCardiol.2020.06630 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|